Issue of Equity RNS14 Apr 2022 12:43
Just now.
Avacta Group plc (AIM: AVCT), a clinical stage oncology company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, today announces that following the exercise of share options by an employee it has issued and allotted in total 91,000 new ordinary shares of 10 pence each in the Company ("Ordinary Shares").
Application will be made for the Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on or around 22 April 2022 ("Admission"). The Ordinary Shares will rank pari passu with the existing Ordinary Shares of the Company.